Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

FHS
March 5, 2025
3:48 am

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 program.

2Seventy Bio sees highest filings and grants during October in Q4 2023

Share this article 2Seventy Bio has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with five publications in Q4 2023 The World Intellectual

February 27, 2024

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD | Psychedelic Invest

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs,

August 24, 2023

Underdiagnosed and undertreated, young Black males with ADHD get left behind

As a kid, Wesley Jackson Wade should have been set up to succeed. His father was a novelist and corporate sales director and his mother

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.